Le Lézard
Classified in: Health, Science and technology
Subject: Business Update

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 6 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the continued development of the Company's pipeline.

Up to 14,500 shares of UroGen's common stock are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee's continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen's 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSU grants were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.


These press releases may also interest you

23 sep 2023
Flow Diversion Aneurysm Treatment Market to grow by USD 2.11 billion from 2022 to 2027, North America to account for 38% of market growth - Technavio
The flow diversion aneurysm treatment market size is expected to grow by USD 2.11 billion from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of  8.8% during the forecast period, according to Technavio Research....

23 sep 2023
Dietary Supplements Market to grow by USD 61.4 billion between 2022 to 2027, Increasing adoption of healthy eating habits is notably driving the dietary supplements market. - Technavio
The dietary supplements market size is expected to grow by USD 61.4 billion from 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 8.16% during the forecast period. Increasing adoption of...

23 sep 2023
African leaders warn of deadly malaria emergency and call for urgent action to address unprecedented funding shortfall
African Union Heads of State and Government, global health leaders and development partners...

23 sep 2023
/C O R R E C T I O N -- Alliance du personnel professionnel et technique de la santé et des services sociaux (APTS)/
In the news release, Public-sector contract talks - Tens of thousands demonstrate in Montréal to defend public services, issued 23-Sep-2023 by Alliance du personnel professionnel et technique de la santé et des services sociaux (APTS) over PR...

23 sep 2023
Racing to change the future of youth mental health
More than 7,500 participants took a giant step forward for youth mental health today, crossing the finish line for the 11th anniversary of RBC Race for the Kids in Toronto. Collectively they raised $2.5 million in support of Family Navigation Project...

23 sep 2023
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The...

More news about Health...


News published on and distributed by: